 Proto-Oncogene Proteins c-ret
"Proto-Oncogene Proteins c-ret" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.
| Descriptor ID |
D051096
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.087 D12.776.543.750.060.217 D12.776.624.664.700.194
|
| Concept/Terms |
Proto-Oncogene Proteins c-ret- Proto-Oncogene Proteins c-ret
- Proto Oncogene Proteins c ret
- c-ret, Proto-Oncogene Proteins
- ret Proto-Oncogene Proteins
- Proto-Oncogene Proteins, ret
- ret Proto Oncogene Proteins
- Proto-Oncogene Protein Ret
- Proto Oncogene Protein Ret
- Ret, Proto-Oncogene Protein
- Receptor Tyrosine Kinase RET
- c-ret Protein
- Proto-Oncogene Protein c-ret
- Proto Oncogene Protein c ret
- c-ret, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-ret".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-ret".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-ret" by people in UAMS Profiles by year, and whether "Proto-Oncogene Proteins c-ret" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 2 | 0 | 2 | | 2021 | 3 | 0 | 3 | | 2020 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-ret" by people in Profiles over the past ten years.
-
Acharya B, Frett B. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present). Expert Opin Ther Pat. 2022 Oct; 32(10):1067-1077.
-
Zhang L, Moccia M, Briggs DC, Bharate JB, Lakkaniga NR, Knowles P, Yan W, Tran P, Kharbanda A, Wang X, Leung YK, Frett B, Santoro M, McDonald NQ, Carlomagno F, Li HY. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. J Med Chem. 2022 01 27; 65(2):1536-1551.
-
Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J Med Chem. 2021 08 26; 64(16):11747-11773.
-
Moccia M, Yang D, Lakkaniga NR, Frett B, McConnell N, Zhang L, Brescia A, Federico G, Zhang L, Salerno P, Santoro M, Li HY, Carlomagno F. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Sci Rep. 2021 08 09; 11(1):16103.
-
Saha D, Ryan KR, Lakkaniga NR, Smith EL, Frett B. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem. 2021 05 18; 16(10):1605-1608.
-
Lakkaniga NR, Gunaganti N, Zhang L, Belachew B, Frett B, Leung YK, Li HY. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15; 206:112691.
-
Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. J Med Chem. 2020 05 14; 63(9):4506-4516.
-
Ospina NS, Maraka S, Donegan D, Morris JC. Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation. Thyroid. 2017 10; 27(10):1332-1334.
-
Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, Li HY. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. Angew Chem Int Ed Engl. 2015 Jul 20; 54(30):8717-21.
-
Burdine LJ, Burdine MS, Moreland L, Fogel B, Orr LM, James J, Turnage RH, Tackett AJ. Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway. PLoS One. 2015; 10(6):e0127943.
-
Frett B, Moccia M, Carlomagno F, Santoro M, Li HY. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. Eur J Med Chem. 2014 Oct 30; 86:714-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|